Medigus Ltd. (NASDAQ:MDGS – Get Rating) declared a Not Available dividend on Thursday, December 8th, Zacks reports. Shareholders of record on Tuesday, December 20th will be paid a dividend of 0.85 per share on Wednesday, December 28th. The ex-dividend date is Monday, December 19th.
Medigus Price Performance
Shares of MDGS opened at $6.26 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.39 and a quick ratio of 1.33. Medigus has a 1 year low of $4.53 and a 1 year high of $19.50. The company’s fifty day moving average is $6.79 and its two-hundred day moving average is $8.81.
Hedge Funds Weigh In On Medigus
A hedge fund recently bought a new stake in Medigus stock. Virtu Financial LLC purchased a new position in shares of Medigus Ltd. (NASDAQ:MDGS – Get Rating) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 61,809 shares of the company’s stock, valued at approximately $40,000. Virtu Financial LLC owned 0.39% of Medigus as of its most recent SEC filing. 1.21% of the stock is currently owned by institutional investors.
Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities.
- Get a free copy of the StockNews.com research report on Medigus (MDGS)
- Costco vs Amazon: an end of the year showdown
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
Receive News & Ratings for Medigus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigus and related companies with MarketBeat.com's FREE daily email newsletter.